Back to results
US 10,570,377 B2Granted
Oncolytic virus strain
AssigneeReplimune Limited
InventorRobert Coffin
Life of this patent
Estimating the term…
Abstract
The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
Claims22
An oncolytic herpes simplex virus 1 (HSV1) which is
- strain RH018A having the accession number ECCAC 16121904;
- strain RH004A having the accession number ECCAC 16121902;
- strain RH031A having the accession number ECCAC 16121907;
- strain RH040B having the accession number ECCAC 16121908;
- strain RH015A having the accession number ECCAC 16121903;
- strain RH021A having the accession number ECCAC 16121905;
- strain RH023A having the accession number ECCAC 16121906;
- or
- strain RH047A having the accession number ECCAC 16121909 wherein said virus is modified to:
- (1) comprise one or more mutations in one or more viral genes, wherein the one or more mutations result in inhibited replication in normal tissue but still allow replication in tumors;
- (2) to express a heterologous fusogenic protein;
- and/or
- (3) to express an immune stimulatory protein in tumors.
10 more elements
Dependencies are inferred from the claim text.